• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴基斯坦的多发性硬化症

Multiple sclerosis in Pakistan.

作者信息

Wasay M, Ali S, Khatri I A, Hassan A, Asif M, Zakiullah N, Ahmed A, Malik A, Khealani B, Haq A, Fredrikson S

机构信息

The Aga Khan University, and Liaquat National Hospital, Karachi, Pakistan.

出版信息

Mult Scler. 2007 Jun;13(5):668-9. doi: 10.1177/1352458506072339. Epub 2007 Feb 9.

DOI:10.1177/1352458506072339
PMID:17548448
Abstract

We describe retrospective data from the largest series of patients (n=142) with multiple sclerosis (MS) from Pakistan. Mean age at onset was 27 years, with a female to male ratio of 1.45:1. The disease onset was polysymptomatic in 75% patients. Motor weakness was the most common onset symptom (70%), followed by sensory symptoms (45%). Optico-spinal type of MS was seen in only 3% of patients The course was relapsing-remitting (RR) in 81%, primary progressive (PP) in 21%, and secondary progressive (SP) in 4% of patients. Almost three-fourths of the patients were moderately (45%) or severely (31%) disabled at the time of evaluation. Two-thirds of patients with severe disability had a mean disease duration of only 5.2 years. In conclusion, MS is not uncommon in Pakistan, and many patients were found to have severe disability despite short disease duration.

摘要

我们描述了来自巴基斯坦最大系列的多发性硬化症(MS)患者(n = 142)的回顾性数据。发病时的平均年龄为27岁,女性与男性的比例为1.45:1。75%的患者发病时症状多样。运动无力是最常见的首发症状(70%),其次是感觉症状(45%)。仅3%的患者为视神经脊髓型MS。81%的患者病程为复发缓解型(RR),21%为原发进展型(PP),4%为继发进展型(SP)。在评估时,近四分之三的患者有中度(45%)或重度(31%)残疾。三分之二的重度残疾患者平均病程仅5.2年。总之,MS在巴基斯坦并不罕见,而且发现许多患者尽管病程短但仍有严重残疾。

相似文献

1
Multiple sclerosis in Pakistan.巴基斯坦的多发性硬化症
Mult Scler. 2007 Jun;13(5):668-9. doi: 10.1177/1352458506072339. Epub 2007 Feb 9.
2
Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.米托蒽醌治疗三年后304例多发性硬化症患者的临床随访
Mult Scler. 2007 Jun;13(5):626-31. doi: 10.1177/1352458506072543. Epub 2007 Feb 9.
3
Current disease-modifying therapies in multiple sclerosis.目前用于治疗多发性硬化症的疾病修正疗法。
Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138.
4
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.复发缓解型多发性硬化轻度残疾患者的认知障碍及其与疾病指标的关系:多发性硬化认知障碍(COGIMUS)研究的基线结果
Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.
5
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史:一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
6
A reassessment of the plateauing relationship between T2 lesion load and disability in MS.对多发性硬化症中T2病变负荷与残疾之间平稳关系的重新评估。
Neurology. 2009 Nov 10;73(19):1538-42. doi: 10.1212/WNL.0b013e3181c06679. Epub 2009 Sep 30.
7
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?疾病修正药物在延缓复发型多发性硬化症进展方面的效果如何?
Neurology. 2007 Oct 9;69(15):1498-507. doi: 10.1212/01.wnl.0000271884.11129.f3. Epub 2007 Aug 15.
8
Factors associated with the risk of secondary progression in multiple sclerosis.与多发性硬化症继发进展风险相关的因素。
Mult Scler. 2008 Jul;14(6):799-803. doi: 10.1177/1352458508089361. Epub 2008 Jun 23.
9
[Mitoxantrone].[米托蒽醌]
Neurologia. 2003 Jul-Aug;18(6):318-23.
10
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.比较研究米托蒽醌在复发缓解型和继发进展型多发性硬化症患者中的疗效特征。
Mult Scler. 2010 Dec;16(12):1490-9. doi: 10.1177/1352458510379613. Epub 2010 Sep 1.

引用本文的文献

1
Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China.中国多发性硬化症在流行病学、临床特征及治疗方面的最新进展
Ther Adv Neurol Disord. 2023 Sep 15;16:17562864231193816. doi: 10.1177/17562864231193816. eCollection 2023.
2
Evaluation of CSF kappa free light chains for the diagnosis of multiple sclerosis (MS): a comparison with oligoclonal bands (OCB) detection via isoelectric focusing (IEF) coupled with immunoblotting.脑脊液游离轻链 κ 对多发性硬化症(MS)的诊断评估:与等电聚焦(IEF)结合免疫印迹检测寡克隆带(OCB)的比较。
J Clin Pathol. 2023 May;76(5):353-356. doi: 10.1136/jcp-2022-208354. Epub 2022 Sep 21.
3
Presentations and Treatment of Multiple Sclerosis in Pakistan: A Retrospective Review of 188 Cases.
巴基斯坦多发性硬化症的临床表现与治疗:188例回顾性研究
Int J MS Care. 2022 Sep-Oct;24(5):vi. doi: 10.7224/1537-2073.2022-008. Epub 2022 Aug 15.
4
Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis.三种疲劳量表在波斯语多发性硬化症患者中的心理测量特性比较
Int J MS Care. 2021 Jan-Feb;23(1):8-15. doi: 10.7224/1537-2073.2019-051. Epub 2020 Feb 14.
5
Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.斯里兰卡鞘内抗体反应显著低下的多发性硬化症患者。
Mult Scler Int. 2018 Feb 28;2018:5342936. doi: 10.1155/2018/5342936. eCollection 2018.
6
Incidence of Radiologically Isolated Syndrome: A Population-Based Study.放射学孤立综合征的发病率:一项基于人群的研究。
AJNR Am J Neuroradiol. 2016 Jun;37(6):1017-22. doi: 10.3174/ajnr.A4660. Epub 2016 Feb 4.